BruceEvanJohnsonMD

PubMed

• 1 citations
  From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later
  James L. Mulshine, Peter Ujhazy, Melissa Antman, Christine M. Burgess, Igor Kuzmin, Paul A. Bunn, Bruce E. Johnson, Jack A. Roth, Harvey I. Pass, Sheila M. Ross, Carol...> ;Journal of Cellular Biochemistry. 2020 Aug 1
• 16 citations
  A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors.
  Slyper, M., Porter, C. B., Ashenberg, O., Waldman, J., Drokhlyansky, E., Wakiro, I., Smillie, C., Smith-Rosario, G., Wu, J., Dionne, D., Vigneau, S., Jané-Valbuena, J....> ;Nature medicine. 2020 May 15
• 17 citations
  Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma
  David Shih, Naema Nayyar, Ivanna Bihun, Ibiayi Dagogo-Jack, Corey M. Gill, Elisa Aquilanti, Mia Bertalan, Alexander Kaplan, Megan R. D'Andrea, Ugonma Chukwueke, Franzi...> ;Nature Genetics. 2020 Mar 23
• The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer.
  Sophia C. Kamran, Thibaud P. Coroller, N. Milani, Vishesh Agrawal, Elizabeth H. Baldini, Aileen B. Chen, Bruce E. Johnson, David Kozono, Idalid Franco, Nitish Chopra, ...> ;Radiation Oncology. 2020 Jan 14
• Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib.
  Mizuki Nishino, Tomoyuki Hida, Sasha Kravets, Suzanne E. Dahlberg, Christine A. Lydon, Hiroto Hatabu, Bruce E. Johnson, Mark M. Awad> ;European Journal of Radiology Open. 2020 Jan 1
• Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials
  Pedro Exman, Ana C. Garrido-Castro, Melissa E. Hughes, Rachel A. Freedman, Tianyu Li, Lorenzo Trippa, Brittany L. Bychkovsky, Romualdo Barroso-Sousa, Simona Di Lascio,...> ;JCO precision oncology. 2019 Nov 15
• M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome
  Hyesun Park, Suzanne E. Dahlberg, Christine A. Lydon, Tetsuro Araki, Hiroto Hatabu, Michael S. Rabin, Bruce E. Johnson, Mizuki Nishino> ;Oncologist. 2019 Aug 1
• 11 citations
  MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Conso...
  Guo, R., Berry, L. D., Aisner, D. L., Sheren, J., Boyle, T., Bunn, P. A., Johnson, B. E., Kwiatkowski, D. J., Drilon, A., Sholl, L. M., Kris, M. G.> ;Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Jun 23
• Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
  Badi El Osta, Madhusmita Behera, Sungjin Kim, Lynne D. Berry, Gabriel Sica, Rathi N. Pillai, Taofeek K. Owonikoko, Mark G. Kris, Bruce E. Johnson, David J. Kwiatkowski...> ;Journal of Thoracic Oncology. 2019 May 1
• Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome.
  Araki, T.,Dahlberg, S. E.,Hida, T.,Lydon, C. A.,Rabin, M. S.,Hatabu, H.,Johnson, B. E.,Nishino, M.> ;Eur J Radiol Open. 2019 Apr 16
• 15 citations
  Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
  Ricciuti, B., Kravets, S., Dahlberg, S. E., Umeton, R., Albayrak, A., Subegdjo, S. J., Johnson, B. E., Nishino, M., Sholl, L. M., Awad, M. M.> ;Journal for immunotherapy of cancer. 2019 Mar 30
• Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
  Horn, L.,Bauml, J.,Forde, P. M.,Davis, K. L.,Myall, N. J.,Sasane, M.,Dalal, A.,Culver, K.,Wozniak, A. J.,Baik, C. S.,Mutebi, A.,Zhang, P.,Wakelee, H. A.,Johnson, B. E.> ;Lung Cancer. 2019 Jan 16
• Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm.
  Nishino, M.,Wakai, S.,Hida, T.,Dahlberg, S. E.,Ozaki, M.,Hatabu, H.,Tachizaki, H.,Johnson, B. E.> ;Eur J Radiol. 2018 Dec 12
• Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy.
  Gill, R. R.,Murphy, D. J.,Kravets, S.,Sholl, L. M.,Janne, P. A.,Johnson, B. E.> ;J Surg Oncol. 2018 Sep 28
• 5 citations
  A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.
  Bryan M. Burt, William G. Richards, Hyun-Sung Lee, Sylvia Bartel, Marcelo C. DaSilva, Ritu R. Gill, Michael T. Jaklitsch, Bruce E. Johnson, Scott J. Swanson, Raphael B...> ;Journal of Thoracic Oncology. 2018 Sep 1
• 34 citations
  The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
  Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., Haura, E., Politi...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Dec 9
• 22 citations
  HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
  Rathi N. Pillai, Madhusmita Behera, Lynne D. Berry, Michael R. Rossi, Mark G. Kris, Bruce E. Johnson, Paul A. Bunn, Suresh S. Ramalingam, Fadlo R. Khuri> ;Cancer. 2017 Nov 1
• 105 citations
  Dabrafenib plus Trametinib in Patients with Previously Untreated BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer: An Open-Label, Phase 2 Trial
  Bruce Johnson, MD> ;The Lancet. 2017 Sep 19
• 1 citations
  Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib.
  Mizuki Nishino, Adrian G. Sacher, Leena Gandhi, Zhao Chen, Esra A. Akbay, Andriy Fedorov, Carl F. Westin, Hiroto Hatabu, Bruce E. Johnson, Peter S. Hammerman, Kwok-Kin...> ;European Journal of Radiology. 2017 Mar 1
• 30 citations
  Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
  Curtis R. Chong, Magda Bahcall, Marzia Capelletti, T. Kosaka, Dalia Ercan, Taebo Sim, Lynette M. Sholl, Mizuki Nishino, Bruce E. Johnson, Nathanael S. Gray, Pasi A. Jänne> ;Clinical Cancer Research. 2017 Jan 1
• 18 citations
  A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
  Masahiko Yanagita, Amanda J. Redig, Cloud P. Paweletz, Suzanne E. Dahlberg, Allison O'Connell, Nora Feeney, Myriam Taibi, David Boucher, Geoffrey R. Oxnard, Bruce E. J...> ;Clinical Cancer Research. 2016 Dec 15
• Institutional implementation of clinical tumor profiling on an unselected cancer population
  Lynette M. Sholl, Khanh Do, Priyanka Shivdasani, Ethan Cerami, Adrian M. Dubuc, Frank C. Kuo, Elizabeth Garcia, Yonghui Jia, Phani K. Davineni, Ryan P. Abo, Trevor J. ...> ;JCI insight. 2016 Nov 17
• 5 citations
  Divide and Conquer to Treat Lung Cancer
  Bruce E. Johnson> ;The New England Journal of Medicine. 2016 Oct 8
• 4 citations
  Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotini...
  Amanda J. Redig, Daniel B. Costa, Myriam Taibi, David Boucher, Bruce E. Johnson, Pasi A. Jänne, David M. Jackman> ;JAMA Oncology. 2016 Sep 1
• Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
  Planchard, D.,Kim, T. M.,Mazieres, J.,Quoix, E.,Riely, G.,Barlesi, F.,Souquet, P. J.,Smit, E. F.,Groen, H. J.,Kelly, R. J.,Cho, B. C.,Socinski, M. A.,Pandite, L.,Nase,...> ;Lancet Oncol.. 2016 Apr 16
• Join now to see all

Lectures

• Welcome and Introductions 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/1/2019